TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11104315
Drug: Psychosocial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatment for anxious ADHD children
Study: 11104315
Drug: Medication response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Medication response
Study: 8247036
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of cisplatin (100 mg/m²) and cyclophosphamide (300 mg/m²)
Study: 8247036
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of cisplatin (80 mg/m²) and cyclophosphamide (225 mg/m²)
Study: 8247036
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of cisplatin and cyclophosphamide
Study: 8247036
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of cisplatin and cyclophosphamide
Study: 30420969
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus Oral Hypoglycemic Agents (OHAs)
Study: 30420969
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus OHAs
Study: 29944308
Drug: Monthly Sulphadoxine-Pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly Sulphadoxine-Pyrimethamine (SP)
Study: 29944308
Drug: Daily Proguanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Proguanil
Study: 18539666
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of triamcinolone acetonide, bupivacaine, and epinephrine
Study: 18539666
Drug: Injection mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection mixture without triamcinolone (Control)
Study: 12676261
Drug: Amifostine 500
Normalized name: amifostine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine 500 mg i.v. prior to each radiotherapy fraction
Study: 11077135
Drug: L-arginine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (6 g/24 h for 3 days)
Study: 1348663
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 275 mg (two capsules)
Study: 1348663
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two identical capsules)
Study: 6140355
Drug: Insulin-dependent diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetic women who later acquired other endocrine disease
Study: 6140355
Drug: Insulin-dependent diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetic women without other endocrine disease
Study: 31356450
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction (MBSR) plus treatment-as-usual (TAU)
Study: 22529301
Drug: ALVAC‐HIV (vCP1521)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC‐HIV (vCP1521) and AIDSVAX B/E vaccine
Study: 12427399
Drug: Intranasal estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal estradiol 300 microg/day (one spray delivery of 150 microg per nostril)
Study: 7723351
Drug: Buflomedil 50
Normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil 50 mg
Study: 7723351
Drug: Buflomedil 100
Normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil 100 mg
Study: 7723351
Drug: Buflomedil 200
Normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil 200 mg
Study: 7034161
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone (Triolandren, 348 mg)
Study: 7034161
Drug: Testosterone propionate
Normalized name: Testosterone Propionate
DrugBank: Testosterone propionate (DB01420)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone propionate injections (84 mg every other day)
Study: 7034161
Drug: Peroral testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroral testosterone administration (800 mg micronized free testosterone daily)
Study: 31455936
Drug: Dependence on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dependence on drug retailers, self-medication, and traditional healers
Study: 15126538
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and resistance training three times a week
Study: 2792461
Drug: 1 alpha‐OHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 alpha‐OHD group (0.75 micrograms of 1 alpha‐OHD and 400 mg of calcium daily)
Study: 2792461
Drug: Thiazide group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide group (1 alpha‐OHD, calcium and 4 mg of trichlormethiazide)
Study: 2792461
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for osteoporosis)
Study: 800385
Drug: 0.05% diflorasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% diflorasone diacetate cream
Study: 22926233
Drug: Zileuton ER
Normalized name: zileuton Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton ER 2400 mg/d
Study: 19522258
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (M group, n=29)
Study: 15191153
Drug: Lidocaine intradermal
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine intradermal injection
Study: 15191153
Drug: Saline intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline intradermal injection (Control)
Study: 11703413
Drug: GP V‐specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP V‐specific antibodies
Study: 7868978
Drug: Dietary cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cholesterol 0 mg (no fat, no cholesterol)
Study: 7868978
Drug: Dietary cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cholesterol 140 mg
Study: 7868978
Drug: Dietary cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cholesterol 280 mg
Study: 7868978
Drug: Dietary cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cholesterol 710 mg
Study: 29306945
Drug: Weekly semistandardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly semistandardized e‐mail feedback from psychologists (individual counseling)
Study: 27874934
Drug: High-frequency oscillatory
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency oscillatory ventilation combined with inhalational NO therapy
Study: 20004661
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg farglitazar
Study: 20004661
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg farglitazar
Study: 12677095
Drug: Drug-free hydrophilic
Normalized name: PSYLLIUM HYDROPHILIC MUCILLOID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free hydrophilic microemulsion (ME)
Study: 12677095
Drug: Drug-free lipophilic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free lipophilic microemulsion (ME)
Study: 12677095
Drug: 5% salicylic
Normalized name: salicylic acid 285 mg in 1 mL TOPICAL SOLUTION [28.5% Salicylic Acid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% salicylic acid gel
Study: 14728001
Drug: Oral glycoprotein
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glycoprotein IIb/IIIa inhibitors
Study: 25695061
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg before induction of anesthesia)
Study: 25695061
Drug: Subhypnotic propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subhypnotic propofol (1 mg/kg/h during operation)
Study: 25695061
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10% intralipid infusion)
Study: 15364042
Drug: Lamotrigine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (400 mg/day)
Study: 11056241
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) as a daily oral dose of estradiol, 2 mg, and norethisterone acetate, 1 mg, plus monthly subcutaneous implants of goserelin acetate for up to 2 years.
Study: 11056241
Drug: Monthly subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly subcutaneous implants of goserelin acetate for up to 2 years without HRT.
Study: 8822684
Drug: Clonidine patch
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine patch delivering 0.2mg/d
Study: 30137193
Drug: Lefitolimod maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lefitolimod maintenance therapy
Study: 27437913
Drug: L-thyroxine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine for 3-6 months
Study: 18275866
Drug: Injection duration
Normalized name: clonidine Injection [Duraclon]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection duration of 25 s
Study: 18275866
Drug: Injection duration
Normalized name: clonidine Injection [Duraclon]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection duration of 30 s
Study: 18275866
Drug: Injection duration
Normalized name: clonidine Injection [Duraclon]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection duration of 35 s
Study: 18275866
Drug: Injection duration
Normalized name: clonidine Injection [Duraclon]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection duration of 40 s
Study: 18275866
Drug: Injection duration
Normalized name: clonidine Injection [Duraclon]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection duration of 45 s
Study: 7513512
Drug: Tranilast 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast 300 mg daily for 6 to 7 weeks before the onset of the pollen season and continuously during the season
Study: 7513512
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication including tranilast until the onset of clinical symptoms in season
Study: 3743153
Drug: albuterol administered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: albuterol administered by metered‐dose inhaler
Study: 3743153
Drug: albuterol administered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: albuterol administered by ultrasonic nebulizer
Study: 3743153
Drug: Freon (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freon (placebo effect from metered‐dose inhaler)
Study: 3743153
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: isotonic saline solution (placebo effect from ultrasonic nebulizer)
Study: 18672629
Drug: 0.9 mg
Normalized name: estradiol 0.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg of atropine plus 2.5 mg of neostigmine
Study: 18672629
Drug: 1.2 mg
Normalized name: RNA 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg of atropine plus 2.5 mg of neostigmine
Study: 11147930
Drug: Amantadine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine treatment
Study: 8741958
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg cocaine
Study: 8741958
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg cocaine
Study: 8741958
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg placebo
Study: 26537369
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no topical antibiotics)
Study: 29615058
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) treatment
Study: 27050475
Drug: Early intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intervention treatment
Study: 25651378
Drug: Midazolam (CYP3A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (CYP3A probe drug)
Study: 23842591
Drug: Low-dose triiodothyronine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose triiodothyronine (0.5 mcg/kg orally every 24 hr for 3 days)
Study: 23842591
Drug: High-dose triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose triiodothyronine (0.5 mcg/kg orally every 12 hr for 3 days)
Study: 20702794
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate at therapeutic levels (0.4‐0.8 mEq/L)
Study: 20702794
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate at subtherapeutic levels (0.2‐0.4 mEq/L)
Study: 16263254
Drug: beta(2)-agonist therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta(2)-agonist therapy
Study: 14597974
Drug: Recombinant Nematode
Normalized name: Recombinant nematode anticoagulant protein-2
DrugBank: Anpocogin (DB06552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) at doses ranging from 0.3 to 5 micro g/kg
Study: 14597974
Drug: Recombinant Nematode
Normalized name: Recombinant nematode anticoagulant protein-2
DrugBank: Anpocogin (DB06552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Nematode Anticoagulant Protein c2 (rNAPc2)
Study: 1486159
Drug: Lignocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine spray 50 mg (Group A)
Study: 1486159
Drug: Lignocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine spray 100 mg (Group B)
Study: 1486159
Drug: Lignocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine spray 200 mg (Group C)
Study: 1486159
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no lignocaine spray)
Study: 23265758
Drug: Novel injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel injection approach
Study: 23265758
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection approach
Study: 21764203
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of warfarin without interruption (group 1)
Study: 21764203
Drug: Warfarin bridged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin bridged with low-molecular-weight heparin (group 2)
Study: 21764203
Drug: Warfarin bridged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin bridged with unfractionated heparin (group 3)
Study: 19295955
Drug: Carbohydrate-electrolyte drink
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte drink containing 36.2 mmol/L sodium (HNa)
Study: 19295955
Drug: Carbohydrate-electrolyte drink
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte drink containing 19.9 mmol/L sodium (LNa)
Study: 14759641
Drug: Acetyl L-carnitine
Normalized name: Nature's Way Acetyl L-Carnitine Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl L-carnitine (ALCAR) 1 g twice daily
Study: 9447899
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g t.i.d.)
Study: 9447899
Drug: Imipenem/cilastatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (1 g t.i.d.)
Study: 7639373
Drug: Subcutaneous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous lidocaine (10 mL 1%)
Study: 7639373
Drug: Subfascial lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subfascial lidocaine (10 mL 1%)
Study: 3358883
Drug: Calcium carbimide
Normalized name: calcium carbimide
DrugBank: Calcium carbimide (DB09116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium carbimide (CC) 50 mg
Study: 29438682
Drug: Serum copper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum copper concentrations >24 μmol/L
Study: 17136298
Drug: Leukotriene antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Leukotriene antagonists (LTA)
Study: 17136298
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids + long‐acting Beta2 agonists
Study: 8821373
Drug: Memantine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (20 mg, single-dose application)
Study: 1563211
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 micrograms as a single dose or q.i.d. as a multiple dose)
Study: 1563211
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg single-dose administration or 50 mg t.i.d. multiple-dose administration)
Study: 6860527
Drug: Long-acting propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting propranolol 160 mg daily
Study: 6860527
Drug: Conventional propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional propranolol 80 mg twice daily
Study: 6860527
Drug: Conventional propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional propranolol 160 mg daily
Study: 29807629
Drug: Subdissociative intravenous-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdissociative intravenous-dose ketamine (SDK) at 0.3 mg/kg
Study: 29807629
Drug: Morphine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine at 0.1 mg/kg
Study: 27560168
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg for 4 weeks, then 45 mg for 8 weeks)
Study: 24493296
Drug: Single-stage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-stage treatment (laparoscopic cholecystectomy and CBD exploration at the same operation)
Study: 24493296
Drug: Two-stage treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage treatment (endoscopic stone clearance followed by laparoscopic cholecystectomy 2-5 days later)
Study: 24493296
Drug: Single-stage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-stage treatment
Study: 19261314
Drug: Artesunate+sulfadoxine/pyrimethamine (AS+SP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate+sulfadoxine/pyrimethamine (AS+SP) (4 mg/kg AS for 3 consecutive days+25 mg sulfadoxine on Day 0)
Study: 19261314
Drug: Praziquantel (PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (PZQ) (40 mg/kg)
Study: 7922999
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial embolization (TAE) with cisplatin (50 mg) mixed with Lipiodol (5-15 ml) and gelfoam pieces.
Study: 3072223
Drug: Nifedipine 5
Normalized name: nifedipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 5 mg 3 times daily
Study: 12501067
Drug: Active magnets
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active magnets (500 G) applied to abdominal trigger points for 24 hours per day for 4 weeks
Study: 31756716
Drug: Mindfulness training
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness training with daily text prompts to practice mindfulness for 10 minutes
Study: 29846278
Drug: Cooling treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling treatment (cooling gel cuff)
Study: 24687385
Drug: PTH(1-84) 100
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH(1-84) 100 μg/d s.c.
Study: 22583743
Drug: Dry powder
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder device for inhaled tobramycin
Study: 18848176
Drug: Electronic monitoring
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic monitoring of drug adherence (Medication Event Monitoring System)
Study: 12439472
Drug: Index of
Normalized name: gr pol-orc/sw ver/rye/Kent/tim 100 index of reactivity SUBLINGUAL TABLET, SUBLINGUAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Index of Orthodontic Treatment Need (IOTN) instruction
Study: 10037249
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment at a daily dose of 0.1 IU/kg (n=26) or 0.2 IU/kg (n=7) body weight
Study: 7127998
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 mg b.i.d. for 12 weeks, increased to 0.2 mg for 12 weeks)
Study: 7127998
Drug: Hydrochlorothiazide (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (24 mg b.i.d. for 12 weeks, increased to 50 mg for 12 weeks)
Study: 17218618
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for 4 to 6 weeks
Study: 17218618
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with OSA before CPAP therapy